Skip to main content
Fig. 5 | Cost Effectiveness and Resource Allocation

Fig. 5

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

Fig. 5

Probabilistic results of the incremental cost-effectiveness differences between treatment with ACTH and TCH for a cohort of 1000 Breast cancer patients.The vertical axes represent the incremental costs.The horizontal axes represent the incremental quality-adjusted life years (QALYs) gained.The data points below the willingness-to-pay (ceiling ratio) threshold represented by the oblique line reflect simulations in which the cost per QALY gained with TCH treatment was below the Chinese cost-effectiveness (C/E) threshold of $20,000. For example, the TCH strategy would be cost-effective when compared with alternative strategies if a patient treated with TCH gained 1 incremental QALY and the incremental cost was lower than $20,000

Back to article page
\